Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determining drug effects. Positron emission tomography (PET) imaging using zirconium-89 radiolabeled monoclonal antibodies (mAbs), also referred to as zirconium-89 (89Zr)-immuno-PET, provides a potential biomarker to measure target expression and verify optimal delivery of targeted agents to tumors. Antibody-drug conjugates (ADCs) combine the high affinity and specificity of mAbs with the potency of cytotoxic drugs to target tumor-expressing antigen and destroy cancer cells. Thus, 89Zr-immuno-PET of whole-body biodistribution, pharmacokinetics, and tumor targeting of antibodies and ADCs to predict toxicity and efficacy could help guide individualized treatment. Here, we review how 89Zr-immuno-PET is being used as a companion diagnostic with the development of ADCs. Furthermore, we discuss how 89Zr-immuno-PET may be utilized in future clinical trials as an adjunct tool with novel ADCs to select cancer patients who have the greatest potential to benefit from treatment and improve ADC dosing regimens.

中文翻译：

---

Immuno-PET在抗体-药物偶联物开发中的应用。

靶向疗法在癌症治疗方面具有广阔的前景，与患者选择工具结合使用时可能会显示出更高的疗效。识别可能的反应者的临床影响包括减少不必要和无效治疗的数量以及更准确地确定药物作用。使用锆89放射性标记的单克隆抗体（mAb）（也称为锆89（89Zr）-免疫PET）进行正电子发射断层扫描（PET）成像，可提供潜在的生物标记物，用于测量靶标表达并验证靶向药物向肿瘤的最佳递送。抗体-药物偶联物（ADC）将mAb的高亲和力和特异性与细胞毒性药物靶向表达肿瘤的抗原并破坏癌细胞的能力结合在一起。因此，全身生物分布，药代动力学的89Zr免疫PET 抗体和ADC靶向肿瘤以预测毒性和功效可帮助指导个体化治疗。在这里，我们回顾了如何将89Zr-immuno-PET与ADC的开发一起用于诊断。此外，我们讨论了如何在未来的临床试验中将89Zr-immuno-PET用作新型ADC的辅助工具，以选择最有可能从治疗中受益并改善ADC给药方案的癌症患者。